Drug Approval | June 24, 2022
Rivaroxaban approved in Japan for patients with PAD after revascularisation
It´s the first trial to demonstrate the benefits of dual pathway inhibition
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Many kids who have heart transplants live a normal, healthy life once they recover from surgery.
Glenmark is the first company in India to market the innovative FDC of Indacaterol
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Subscribe To Our Newsletter & Stay Updated
